Table 1.
Patient | Efficacy score (%) | Day | Time to peak headache (duration) | Headache characteristics | Associated symptoms | Mimics usual migraine | Migraine-like attack (onset) | Treatment (time)/efficacy |
---|---|---|---|---|---|---|---|---|
1 CM |
50/75/0/25 |
CGRP Placeboa Spon |
3 h (4 h) 80 min (NA) |
Bilat/10/Throb+Pres/+ Bilat/6/Pres/M Bilat/Throb/+ |
+/+/+ +/+/− +/+/+ |
Yes No |
Yes (20min) No |
Sumatriptan 100 mg (6 h) / No NR |
2 EM |
100/100/ 100/100 |
CGRP Placebo Spon |
2 h (NA)b None |
Bilat/10/Pres/+ | −/+/− | Yes | Yes (20 min) | Sumatriptan 50 mg (2 h) / Yes |
Right/Throb/+ | +/+/− | |||||||
3 EM |
100/0/0/100 |
CGRP Placebo Spon |
3 h (1 h) 30 min (1h) |
Bilat/7/Throb/+ Bilat/3/Pres/M Left/ Throb/+ |
+/+/+ −/+/− +/+/+ |
Yes No |
Yes (70 min) No |
Sumatriptan 50 mg (3 h) / Yes, Treo (9 h) / NR None |
4 EM |
100/50/0/100 |
CGRPc Placebo Spon |
6 h (1 h) 10 h (NA) |
Bilat/7/Throb+Pres/NR Left/5/Throb/+ Left/Throb/+ |
+/+/+ −/−/+ +/+/+ |
NR Yes |
Yes (5 h) No (NA)e |
2 x KP (5 h) / No, Riza 10 mg (6 h) / NRd, KP (10 h) / Yes Riza + 2 x KP (10 h) / NRf |
5 EM |
0/25/0/0 |
CGRP Placebo Spon |
3 h (1 h) None |
Bilat/5/Pres/+ Bilat/Throb/+ |
−/+/+ −/+/+ |
Yes | Yes (20 min) | Sumatriptan 100 mg (3 h) / Yes |
6 EM |
75/50/50/75 |
CGRP Placebo Spon |
3 h (2 h) 9 h (2 h) |
Right/4/Pres/− Right/3/NR/- Unilatg/Throb/+ |
−/+/− −/+/− +/+/+ |
Yes Yes |
Yes (2 h) No (NA) |
Zolmitriptan 2.5 mg (3 h) / Yes, 2 x Treo (6 h) / Yes Treo (9 h) / NR |
7 EM |
75/75/0/75 |
CGRP Placebo Spon |
1 h (10 min) 4 h (2 h) |
Right/5/Throb/NR Left/2/Pres/+ Unilat7/Throb/+ |
−/+/− −/+/− +/+/+ |
Yes Yes |
Yes (20 min) No (NA) |
2 x Treo (3 h) / Yes, Sumatriptan 50 mg (4 h) / Yes None |
8 EM |
100/50/75/75 |
CGRP Placebo Spon |
8 h (5 h) 50 min (10 min) |
Left/9/Pres/+ Bilat/2/Pres/M Left/Throb/+ |
+/+/+ −/+/− +/+/+ |
Yes No |
Yes (2 h) No (NA) |
None None |
9 CM |
75/0/75/75 |
CGRP Placebo Spon |
4 h (5 h) None |
Right/2/Throb/+ ᅟ Bilat+Unilath/Throb/+ |
−/−/− ᅟ +/+/+ |
Yes | No (NA)e | None |
10 CM |
100/0/25/100 |
CGRP Placebo Spon |
None None |
Right/Throb/+ | +/+/+ | |||
11 CM |
0/0/0/0 |
CGRP Placebo Spon |
50 min (10 min) None |
Bilat/5/Throb/M Left/Throb/+ |
−/−/− +/+/+ |
No | No (NA) | Panadol Extra + Ibuprofen 600 mg (2 h) / Yes |
12 CM |
50/25/0/25 |
CGRP Placebo Spon |
6 h (1 h) None |
Right/9/Throb/+ Right/Throb/+ |
+/+/+ +/+/+ |
Yes | Yes (40 min) | 2 x Treo + Paracetamol 1 g + Meto 10 mg (6 h) / Yes |
13 CM |
50/50/75/50 |
CGRP Placebo Spon |
80 min (20 min) 7 h (1 h) |
Right/5/Throb/+ Bilat/2/Pres/+ Right/Throb/+ |
−/+/+ −/−/− +/+/+ |
Yes No |
Yes (60 min) No (NA) |
Sumatriptan 100 mg + Naproxen 500 mg (2 h) / Yes None |
Efficacy score: Reduction in migraine days/reduction of the headache intensity/reduction in headache days/reduction in days of used rescue medication. Headache characteristics: Localization/intensity/quality/aggravation. Associated symptoms: Nausea/photophobia/phonophobia. The criteria for a migraine-like attack are described in ‘Methods’. Treatment efficacy: ≥ 50% decrease of headache intensity within 2 h
Bilat Bilateral, Throb Throbbing, Pres Pressing, M Missing data, NR Not reported, CM Chronic migraine, EM Episodic migraine
KP Codeine 30.6 mg + Paracetamol 500 mg, Panadol Extra Paracetamol 500 mg + Caffeine 65 mg, Treo Aspirin 500 mg + Caffeine 50 mg, Meto: Metoclopramide 10 mg, Riza: Rizatriptan 10 mg
a2–12 h data not reported; b 3–4 h data not reported; c 2–12 h data not reported for aggravation and mimics usual migraine; d Sleep at 8–9 h, headache intensity score was 1 at 10 h; e Possible migraine-like attack; f 11–12 h data missing, but reported pain relief and sleep after medication intake; g Unilateral, no side preference; h Shifting between bilateral and unilateral (no side preference)